Its protein expression level is increased in many human cancers such as hepatocarcinomas, digestive adenocarcinomas and ovarian cancers, and its downregulation in p53- and RB-compromised cancer cells can trigger their senescence.1 Further understanding of E2F1 expression regulation would help to develop strategies targeting this protein in cancer cells. The gene discussed is TP53; the disease is cancer.